Jade Jaffar

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9518273/publications.pdf

Version: 2024-02-01

22	656	623734 14	713466 21
papers	citations	h-index	g-index

23	23	23	1190
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Influenza-specific lung-resident memory T cells are proliferative and polyfunctional and maintain diverse TCR profiles. Journal of Clinical Investigation, 2018, 128, 721-733.	8.2	147
2	Mitochondrial dysfunction contributes to the senescent phenotype of <scp>IPF</scp> lung fibroblasts. Journal of Cellular and Molecular Medicine, 2018, 22, 5847-5861.	3.6	65
3	STAT3 Regulates the Onset of Oxidant-induced Senescence in Lung Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 2019, 61, 61-73.	2.9	52
4	Fibulin-1 Predicts Disease Progression in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2014, 146, 1055-1063.	0.8	42
5	Fibulin1C peptide induces cell attachment and extracellular matrix deposition in lung fibroblasts. Scientific Reports, 2015, 5, 9496.	3.3	37
6	Greater cellular stiffness in fibroblasts from patients with idiopathic pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 315, L59-L65.	2.9	37
7	Annexin A2 contributes to lung injury and fibrosis by augmenting factor Xa fibrogenic activity. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 312, L772-L782.	2.9	30
8	Senescence of IPF Lung Fibroblasts Disrupt Alveolar Epithelial Cell Proliferation and Promote Migration in Wound Healing. Pharmaceutics, 2020, 12, 389.	4.5	30
9	Casein Kinase 1Î´/Îµ Inhibitor, PF670462 Attenuates the Fibrogenic Effects of Transforming Growth Factor-Î²2 in Pulmonary Fibrosis. Frontiers in Pharmacology, 2018, 9, 738.	3.5	28
10	Self DNA perpetuates IPF lung fibroblast senescence in a cGAS-dependent manner. Clinical Science, 2020, 134, 889-905.	4.3	28
11	Inhibition of the K_{Ca}3.1 Channel Alleviates Established Pulmonary Fibrosis in a Large Animal Model. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 539-550.	2.9	26
12	The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target in IPF. Scientific Reports, 2017, 7, 41770.	3.3	26
13	Cellular Microenvironment Stiffness Regulates Eicosanoid Production and Signaling Pathways. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 819-830.	2.9	25
14	CXCR4+ cells are increased in lung tissue of patients with idiopathic pulmonary fibrosis. Respiratory Research, 2020, 21, 221.	3.6	23
15	Inhibition of NF-ÎºB by ACT001 reduces fibroblast activity in idiopathic pulmonary fibrosis. Biomedicine and Pharmacotherapy, 2021, 138, 111471.	5.6	15
16	A Quantitative Proteomic Approach to Identify Significantly Altered Protein Networks in the Serum of Patients with Lymphangioleiomyomatosis (LAM). PLoS ONE, 2014, 9, e105365.	2.5	14
17	A Senescence Bystander Effect in Human Lung Fibroblasts. Biomedicines, 2021, 9, 1162.	3.2	12
18	Vascular remodelling in IPF patients and its detrimental effect on lung physiology: potential role of endothelial to mesenchymal transition (EndMT). ERJ Open Research, 2022, 8, 00571-2021.	2.6	12

#	Article	IF	Citations
19	Angiotensin-Converting Enzyme 2 (ACE2), Transmembrane Peptidase Serine 2 (TMPRSS2), and Furin Expression Increases in the Lungs of Patients with Idiopathic Pulmonary Fibrosis (IPF) and Lymphangioleiomyomatosis (LAM): Implications for SARS-CoV-2 (COVID-19) Infections. Journal of Clinical Medicine, 2022, 11, 777.	2.4	4
20	Coagulation factor-XII induces interleukin-6 by primary lung fibroblasts: a role in idiopathic pulmonary fibrosis?. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2022, 322, L258-L272.	2.9	2
21	Establishing CREATE: lessons learned in setting up a training environment for early-career researchers in respiratory medicine. BMC Medical Education, 2022, 22, 136.	2.4	1
22	P073 <break /> The role of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis.. QJM - Monthly Journal of the Association of Physicians, 0, , .	0.5	0